MedTrace Logo

Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis

NCT05733897 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-03-02

No results posted yet for this study

Summary

Nonalcoholic steatohepatitis (NASH) is a serious type of nonalcoholic fatty liver disease (NAFLD), which is characterized by lobular inflammation and apoptosis resulting from hepatic steatosis in the absence of excessive alcohol consumption. If NASH are not controlled well, it will advance to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. However, there is no approved treatments currently.

The investigators aim to clarify whether hydroxychloroquine relieves nonalcoholic steatohepatitis by reviewing medical records from our out-patient-clinic patients who accept the treatment of hydroxychloroquine (Plaquenil®).

Conditions

Interventions

DRUG

hydroxychloroquine

Using hydroxychloroquine to treat nonalcoholic steatohepatitis

Sponsors & Collaborators

  • National Taiwan University

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chung-Jui Huang, Master · Graduate Institute of Pharmacology, College of Medicine, National Taiwan University

  • Feng-Chiao Tsai, Doctor · Graduate Institute of Pharmacology, College of Medicine, National Taiwan University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2025-07-01
Completion
2025-07-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733897 on ClinicalTrials.gov